Valneva announces fda's decision to suspend license of chikungunya vaccine ixchiq® in the u.s.

Saint herblain (france), august 25, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the united states food and drug administration (fda) has suspended the license for ixchiq®, citing four new reports of serious adverse events (saes) consistent with chikungunya-like illness. the suspension of the license is effective immediately and requires valneva to stop shipping and selling of ixchiq® in the united states.
VALN Ratings Summary
VALN Quant Ranking